The broad availability of low cost generics and the size of salesforce needed to cover the market have made hypertension a no-fly zone for most biotechs and even some pharmas. Symplmed Pharmaceuticals LLC is entering the space, not with novel products, but with a web-based platform for selling drugs that is designed to improve patient adherence while reducing costs.

The test case for Symplmed's DyrctAxess marketing platform will be next month's launch of Aceon perindopril, a branded generic angiotensin-converting enzyme (ACE) inhibitor.